<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434135</url>
  </required_header>
  <id_info>
    <org_study_id>SICOG trial 0506</org_study_id>
    <nct_id>NCT00434135</nct_id>
  </id_info>
  <brief_title>Alimta and Gemcitabine in Non-Small Cell Lung Cancer</brief_title>
  <acronym>ANGEL</acronym>
  <official_title>A Phase II Randomized Trial Assessing the Combination of Gemcitabine and Pemetrexed in the First Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern Italy Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Southern Italy Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta&#xD;
      (pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of&#xD;
      a randomized trial, and (2) to compare the GA with the paclitaxel plus gemcitabine (PG&#xD;
      regimen) in terms of toxicity and QoL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with stage IIIB or IV non-small cell lung cancer will be randomly allocated to&#xD;
      receive: (a)PG regimen: paclitaxel 120 mg/sqm followed by gemcitabine 1,000 mg/sqm i.v. on&#xD;
      days 1 &amp; 8 q 3 weeks; (b)GA regimen: gemcitabine 1,250 mg/sqm i.v. on day 1 (plus folinic&#xD;
      acid 350 μg daily orally and vitamin B12 1,000 μg i.m. q 9 weeks), pemetrexed (Alimta®) 500&#xD;
      mg/sqm i.v. on day 8 followed by gemcitabine 1,250 mg/sqm, q 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of patients treated with the gemcitabine plus Alimta regimen</measure>
    <time_frame>after 3 cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of patients treated with gemcitabine plus Alimta regimen</measure>
    <time_frame>at the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of patients treated with gemcitabine plus Alimta regimen</measure>
    <time_frame>after 3 cyces</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Stage IIIB or IV</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine plus pemetrexed, paclitaxel plus gemcitabine</intervention_name>
    <description>gemcitabine 1,250 mg/sqm days 1&amp;8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&amp;8</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically or cytologically confirmed locally advanced (stage IIIB)&#xD;
             or metastatic (stage IV) NSCLC&#xD;
&#xD;
          2. No previous adjuvant or palliative chemotherapy&#xD;
&#xD;
          3. No previous radiotherapy&#xD;
&#xD;
          4. Presence of at least one unidimensionally measurable lesion (Appendix 2)&#xD;
&#xD;
          5. ECOG performance status of 0 or 1 (Appendix 3)&#xD;
&#xD;
          6. Charlson score ≤ 2 (Appendix 4)&#xD;
&#xD;
          7. Adequate bone marrow function (absolute neutrophil count ≥ 2 x 109/L, platelet count ≥&#xD;
             100 x 109/L, and hemoglobin level ≥ 100 g/L), and adequate liver function (bilirubin&#xD;
             level &lt; two times the upper limit of normal, AST and/or ALT &lt; three times the upper&#xD;
             limit of normal, prothrombin time &lt; 1.5 times control), and creatinine clearance ≥ 60&#xD;
             ml/min.&#xD;
&#xD;
          8. Absence of symptomatic CNS metastases (patients with cerebral metastases treated with&#xD;
             brain irradiation may be included), severe cardiac arrhythmia or heart failure, second&#xD;
             or third degree heart block or acute myocardial infarction within 4 months prior to&#xD;
             study entry.&#xD;
&#xD;
          9. No major surgery or pleurodesis within 14 days prior to enrollment.&#xD;
&#xD;
         10. Life expectancy of at least 12 weeks.&#xD;
&#xD;
         11. No previous or concurrent malignancy, except inactive non-melanoma skin cancer, in&#xD;
             situ carcinoma of the cervix, or other cancer if the patient has been disease-free for&#xD;
             more than 5 years.&#xD;
&#xD;
         12. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unstable systemic disease (including active infection, uncontrolled hypertension,&#xD;
             unstable angina, congestive heart failure, serious cardiac arrhythmia requiring&#xD;
             medication, hepatic, renal or metabolic disease).&#xD;
&#xD;
          2. Patients with clinically significant effusions.&#xD;
&#xD;
          3. Any other malignancies within 5 years that could affect therapy evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pasquale Comella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Tumor Institute, Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Tumor Institute</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>February 9, 2007</study_first_submitted>
  <study_first_submitted_qc>February 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2007</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pasquale Comella MD</name_title>
    <organization>Southern Italy Cooperative Oncology Group</organization>
  </responsible_party>
  <keyword>gemcitabine</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

